论文部分内容阅读
Janssen公司推出的新型抗精神病药物—risperidone可能成为继Paul Janssen等于1958年发现haloperidol之后,在精神分裂症治疗上的首次重大突破(这是Janssen公司最近在为庆祝他们在精神病学领域研究30周年所举行的一次学术座谈会上公布的)。该药目前正在欧美国家作三期临床试验,预计两三年内可结束,四年后将投放市场。传统的精神病药大多是多巴胺拮抗剂,对精神分裂症的“显性”(positive)症状如:幻觉、妄想等有特效,但对“隐性”(negative)症状如:情感淡漠,孤癖等则无作用,且伴有锤体束外副作用。 Janssen公司开发的5-羟色胺(5HT_2)拮抗剂—ritansern被用作情感增强剂(moodstrengthening)和抗忧郁药。此药对精神分
Janssen’s new antipsychotic drug, risperidone, may be the first major breakthrough in schizophrenia following Paul Janssen’s discovery of haloperidol in 1958 (this is Janssen’s recent major breakthrough in celebrating their 30th anniversary in psychiatry Held at an academic symposium announced). The drug is currently in Europe and the United States for Phase III clinical trials are expected to be completed within two or three years, will be put on the market four years later. Traditional psychotropic drugs are mostly dopamine antagonists, and have special effects on the “positive” symptoms of schizophrenia such as hallucinations and delusions. However, the negative symptoms such as indifference and solitary apathy No effect, and accompanied by hammer beam side effects. Janssen’s serotonin (5HT_2) antagonist ,ritansern, has been used as a moodstrengthening and antidepressant. This medicine on the spirit points